N-[(Z)-[10-[(Z)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine;hydron;dichloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: N-[(Z)-[10-[(Z)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine;hydron;dichloride
• 化学式: C22H24Cl2N8
• 分子量: 471.4
• InChiKey: KINULKKPVJYRON-VCZQZRGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  97.6
• 氢给体数：
  6
• 氢受体数：
  4

文献信息

• Emulsion compositions for administration of sparingly water soluble ionizable basic hydrophobic drugs
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0214501A2

  公开（公告）日：1987-03-18

  Lipid emulsion form compositions have been formulated and presented to eliminate adverse injection site reactions associated with the intravenous administration of certain sparingly water soluble, hydrophobic, ionizable drugs in mammals and to provide a solubilized drug form for oral, parenteral or intraarticular administration which enhances drug absorption and the therapeutic efficacy of the drug.

  脂质乳剂形式组合物的配制和提出，是为了消除与哺乳动物静脉注射某些稀水溶性、疏水性、可离子化药物有关的注射部位不良反应，并提供一种用于口服、肠外或关节内给药的溶解药物形式，以促进药物的吸收和疗效。
• Tumor specific antibody
  申请人：Viventia Bio Inc.

  公开号：EP2927322A1

  公开（公告）日：2015-10-07

  The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.

  本发明提供了肿瘤特异性抗体重链和轻链互补决定区的氨基酸和核酸序列。此外，本发明还提供了肿瘤特异性抗体和由肿瘤特异性抗体连接毒素或标记物组成的免疫结合剂及其方法和用途。本发明还涉及使用本发明肿瘤特异性抗体的诊断方法和试剂盒。
• Constructs targeting AFP peptide/MHC complexes and uses thereof
  申请人：EUREKA THERAPEUTICS, INC.

  公开号：US10011658B2

  公开（公告）日：2018-07-03

  The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising an AFP peptide and an MHC class I protein. Also provided are methods of making and using these constructs.

  本申请提供了包含抗体分子的构建物，该抗体分子能特异性地与由 AFP 肽和 MHC I 类蛋白组成的复合物结合。本申请还提供了制作和使用这些构建体的方法。
• Anti-CS1 antibodies and antibody drug conjugates
  申请人：AbbVie Biotherapeutics Inc.

  公开号：US10011657B2

  公开（公告）日：2018-07-03

  The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.

  本公开提供了与人类 CS1 结合的抗体和抗体药物共轭物，以及它们在治疗确诊为浆细胞肿瘤（例如多发性骨髓瘤）患者中的用途。
• Dosing strategies for targeting EPCAM positive bladder cancer
  申请人：VIVENTIA BIO INC.

  公开号：US10583198B2

  公开（公告）日：2020-03-10

  The present disclosure provides methods for treatment of bladder cancer. The methods include administering an immunoconjugate to a subject in a dosing regimen that includes an induction phase with twice weekly followed by once weekly dosing, and optionally a maintenance phase. The immunoconjugates useful in the methods provided include immunoconjugates having a binding protein that specifically binds to Ep-CAM and a toxin molecule.

  本公开提供了治疗膀胱癌的方法。这些方法包括在给药方案中向受试者施用免疫结合剂，该给药方案包括诱导阶段，每周两次给药，随后每周一次给药，以及可选的维持阶段。在所提供的方法中有用的免疫结合剂包括具有与 Ep-CAM 和毒素分子特异性结合的结合蛋白的免疫结合剂。